Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases
- PMID: 31809750
- DOI: 10.1016/j.drudis.2019.11.013
Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases
Abstract
Retinal photoreceptors continually endure stresses associated with prolonged light exposure and the metabolic demands of dark adaptation. Although healthy photoreceptors are able to withstand these stresses for several decades, the disease-affected retina functions at a reduced capacity and is at an increased risk for dysfunction. To alleviate cellular and metabolic stressors in degenerative retinal diseases, a new class of drugs that modulate the metabolic activity of the retina have been developed. A clinical candidate in this class (emixustat) has been shown to reduce retinal pathology in various animal models of human retinal disease and is currently under clinical study. Here, we describe the pharmacological properties of emixustat, its mechanisms of action, and potential for use in the treatment of specific retinal diseases.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Development of chiral fluorinated alkyl derivatives of emixustat as drug candidates for the treatment of retinal degenerative diseases.Bioorg Med Chem Lett. 2020 Sep 15;30(18):127421. doi: 10.1016/j.bmcl.2020.127421. Epub 2020 Jul 18. Bioorg Med Chem Lett. 2020. PMID: 32717613 Free PMC article.
-
Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity.PLoS One. 2015 May 13;10(5):e0124940. doi: 10.1371/journal.pone.0124940. eCollection 2015. PLoS One. 2015. PMID: 25970164 Free PMC article.
-
Pharmacotherapy of retinal disease with visual cycle modulators.Expert Opin Pharmacother. 2018 Apr;19(5):471-481. doi: 10.1080/14656566.2018.1448060. Epub 2018 Mar 15. Expert Opin Pharmacother. 2018. PMID: 29542350 Review.
-
Emixustat Reduces Metabolic Demand of Dark Activity in the Retina.Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4924-4930. doi: 10.1167/iovs.19-28194. Invest Ophthalmol Vis Sci. 2019. PMID: 31770432
-
Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.Dev Ophthalmol. 2016;55:302-9. doi: 10.1159/000438954. Epub 2015 Oct 26. Dev Ophthalmol. 2016. PMID: 26501510 Review.
Cited by
-
Retinoid analogs and polyphenols as potential therapeutics for age-related macular degeneration.Exp Biol Med (Maywood). 2020 Nov;245(17):1615-1625. doi: 10.1177/1535370220926938. Epub 2020 May 21. Exp Biol Med (Maywood). 2020. PMID: 32438835 Free PMC article. Review.
-
Tuning the Metabolic Stability of Visual Cycle Modulators through Modification of an RPE65 Recognition Motif.J Med Chem. 2023 Jun 22;66(12):8140-8158. doi: 10.1021/acs.jmedchem.3c00461. Epub 2023 Jun 6. J Med Chem. 2023. PMID: 37279401 Free PMC article.
-
Contribution of Interleukin-17A to Retinal Degenerative Diseases.Front Immunol. 2022 Mar 22;13:847937. doi: 10.3389/fimmu.2022.847937. eCollection 2022. Front Immunol. 2022. PMID: 35392087 Free PMC article. Review.
-
Rational Alteration of Pharmacokinetics of Chiral Fluorinated and Deuterated Derivatives of Emixustat for Retinal Therapy.J Med Chem. 2021 Jun 24;64(12):8287-8302. doi: 10.1021/acs.jmedchem.1c00279. Epub 2021 Jun 3. J Med Chem. 2021. PMID: 34081480 Free PMC article.
-
Development of chiral fluorinated alkyl derivatives of emixustat as drug candidates for the treatment of retinal degenerative diseases.Bioorg Med Chem Lett. 2020 Sep 15;30(18):127421. doi: 10.1016/j.bmcl.2020.127421. Epub 2020 Jul 18. Bioorg Med Chem Lett. 2020. PMID: 32717613 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical